Figure S1. Tumor PD-L1 expression and survival in the camrelizumab plus PC group. Comparison of (A) DFS and (B) OS between patients with tumor PD-L1 expression >50% and those with PD-L1 expression ≤50%. PC, paclitaxel and carboplatin; PD-L1, programmed cell death protein 1 ligand 1; DFS, disease-free survival; OS, overall survival.